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REVIEW
Role of endocannabinoids in regulating drug 
dependence
Abstract: This review will discuss the latest knowledge of how the endocannabinoid system 
might be involved in treating addiction to the most common illicit drugs. Experimental models 
are providing increasing evidence for the pharmacological management of endocannabinoid 
signaling not only to block the direct reinforcing effects of cannabis, opioids, nicotine and ethanol, 
but also for preventing relapse to the various drugs of abuse, including opioids, cocaine, nicotine, 
alcohol and metamphetamine. Preclinical and clinical studies suggest that the endocannabinoid 
system can be manipulated by the CB1 receptor antagonist SR141716A, that might constitute a 
new generation of compounds for treating addiction across different classes of abused drugs.
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Introduction
Drug addiction is a chronic relapsing brain disorder, manifested as an intense desire for 
the drug, with impairment of the ability to control the urges to take the drug, even at 
the expense of serious adverse consequences (Camì and Farré 2003). These behavioral 
abnormalities develop gradually with repeated exposure to a drug of abuse, and can 
persist for months or years after discontinuation of use, suggesting that addiction can 
be considered a form of drug-induced neural plasticity (Nestler 2004).
Several compounds can lead to addictive behavior including opioids, psychostimu-
lants, cannabinoids, alcohol and nicotine, and although their initial mechanism of action 
affects different neurochemical targets, the resulting neural dysregulation involves 
similar neurochemical and neuroanatomical pathways (Hyman and Malenka 2001). 
The limbic component of basal ganglia pathways, the endogenous opioid system and 
the brain-pituitary stress system are all essential for the addictive properties of most 
drugs of abuse, whose interaction with these circuits leads to a common dysregulation 
of brain motivational and reward pathways (Maldonado et al 2006).
The limbic component of the basal ganglia pathway is a common neuronal substrate 
for the reinforcing properties of drugs of abuse and drives the motivational, emotional 
and affective information on behavior (see for review Koob 1992; Di Chiara 1999; 
Koob et al 2004; Pierce et al 2006). The mesocorticolimbic dopaminergic pathway 
(comprising dopaminergic neurons in the ventral tegmental area – VTA – innervating 
the nucleus accumbens – NAc – hippocampus, amygdala, medial prefrontal cortex 
and ventral pallidum), is a vital factor governing the ﬂ  ow of information through the 
limbic circuit comprising the interconnected nuclei. Thus dopamine is considered 
one of the most important actors in the rewarding effects of drugs of abuse, as sug-
gested by the ﬁ  nding that most of the drugs abused by humans raise dopamine levels 
in the NAc, and blockade of dopamine transmission reduces the rewarding effect of 
psychostimulants (see for review Pierce and Kumaresan 2006). Moreover, mesolimbic 
dopaminergic neurons communicate with cerebral areas involved in cognitive functions 
and dopamine release in the forebrain can be considered a learning signal. In the NAc 
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glutamatergic projections from the cerebral cortex, amygdala 
and hippocampus drive information about external situations 
and internal emotional and physiological states, thus contrib-
uting to addiction by consolidating reward-driven behavior 
(Hyman and Malenka 2001; Kauer 2004).
The endocannabinoid system 
and addictive behavior
Besides the importance of the mesocorticolimbic dopami-
nergic system in addiction, the shared mechanisms in the 
development of addictive behavior have not yet been fully 
identiﬁ  ed so this review will focus on recent ﬁ  ndings pointing 
towards a role of the endocannabinoid system in the circuitry 
underlying drug addiction.
Knowledge of the endocannabinoid system has been 
largely boosted since the CB1 receptor was cloned in 1990 
and we now understand that the endocannabinoid system 
consists of cannabinoid receptors, endogenous ligands and 
several proteins responsible for their synthesis and degrada-
tion (see for review Bisogno et al 2005). Two cannabinoid 
receptors, CB1 and CB2 have been cloned and characterized, 
both belonging to the class of G protein-coupled receptors. 
CB1 has been located in the central nervous system and 
peripheral tissues and CB2 appeared mainly in the cells of the 
immune system (Fride and Mechoulam 2003) although it has 
now also been identiﬁ  ed in brainstem, cortex and cerebellum 
neurons (Van Sickle et al 2005).
The most fully characterized endocannabinoid sub-
stances isolated from brain tissue are anandamide (AEA) 
and 2-arachidonylglycerol (2-AG) (Fride and Mechoulam 
2003). Endocannabinoids serve as neuromodulators in many 
physiological processes and once released from postsynaptic 
neurons upon depolarization, they activate presynaptic recep-
tors, resulting in inhibition of the release of both excitatory 
and inhibitory transmitters (see for review Fride 2005). In 
this capacity the endocannabinoid system may have important 
additional roles in the regulation of synaptic brain function.
CB1 receptors are abundant in the brain reward circuitry, 
and the dopaminergic neurons of the mesocorticolimbic 
pathway are regulated by excitatory and inhibitory inputs 
inﬂ  uenced by activation of cannabinoid receptors (see for 
review Gardner 2005). Endocannabinoids released after 
depolarization in the NAc and from dopaminergic neurons 
in the VTA may possibly inﬂ  uence GABAergic and gluta-
matergic afferents by acting as retrograde messengers on 
CB1 receptors.
Wenger et al (2003) reported the presence of cannabinoid 
receptors in tyrosine hydroxylase-expressing neurons (most 
probably dopaminergic neurons) of the NAc, VTA, striatum 
and pyriform cortex, suggesting the endocannabinoid system 
might directly inﬂ  uence dopaminergic reward mechanisms. 
CB1 receptors are present in other areas related to reward 
and motivation (such as the basolateral amygdala and hip-
pocampus) and endocannabinoids induce long-term depres-
sion (LTD) of the inhibitory synapses in the hippocampus, 
contributing to the synaptic plasticity involved in the learn-
ing processes related to addictive behavior (De Vries and 
Schoffelmeer 2005).
The endocannabinoid system is certainly the primary site 
of action for cannabinoid addiction and in fact cannabinoids, 
like other drugs of abuse, induce tolerance and physical 
dependence and activate a rewarding system (see for review 
Parolaro et al 2005; Fattore et al 2005; Gonzalez et al 2005). 
The exact sites and substrates of cannabinoid action in the 
core VTA-medial forebrain bundle (MFB)-NAc reward 
axis and on reward-related behaviors are still not clear but 
there is evidence that cannabinoids enhance brain reward 
substrates, acting on both dopamine-dependent substrates 
in the VTA and dopamine-dependent/independent ones in 
the NAc (Lupica et al 2004).
However, the endocannabinoid system certainly has an 
overall effect on the reward circuitry and participates in the 
rewarding and addictive properties of all prototypical drugs 
of abuse such as opioids, nicotine, alcohol and psychostimu-
lants (cocaine and amphetamine). Animal models of drug 
reward provide evidence of the endogenous cannabinoids’ 
role in the rewarding effects of several addictive drugs, and 
pharmacological manipulation of endocannabinoid tone 
with SR141716A (rimonabant, a speciﬁ  c CB1 receptor 
antagonist) in humans gave positive results (Anthenelli and 
Despres 2004).
Two complementary approaches have been used to 
demonstrate the endocannabinoid system’s role in addictive 
behavior; the ﬁ  rst is a genetic approach evaluating changes 
to the addictive properties of several drugs of abuse in CB1 
knockout mice, and the second is a pharmacological approach 
looking at the effect of SR141716A on drugs’ addictive 
properties. Research in this ﬁ  eld has also gained from the use 
of validated experimental models for the subjective effects 
of drugs (drug discrimination), their rewarding/reinforcing 
properties (intravenous self-administration, conditioned place 
preference – CPP – and intracranial self-stimulation), the 
inﬂ  uence of environmental factors on drug-seeking behav-
ior (CPP, second-order schedules of self-administration, 
reinstatement of extinguished drug-seeking behavior and 
other relapse models), and the withdrawal states associated Neuropsychiatric Disease and Treatment 2007:3(6) 713
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Table 1 Cannabinoid system in opioid addiction
 Drug  Model  Effect  Refs
CB1 agonist  Morphine,  Withdrawal  Attenuation  Hine 1975; Deikel and 
 Methadone       Carder1976;  Vela  1995;
      Ymaguchi  2001;  Del 
      Arco  2002
  Morphine  CPP  Increase   Manzanedo 2004 
 Heroin  SA  Increase  Solinas  2005
    SA (relapse)  Reinstatement  De Vries 2003; Fattore 2003
  Morphine  Withdrawal  Precipitated abstinence  Navarro 1998; Maldonado 
      2002
      Attenuation, no change  Rubino 2000; MasNieto 2001
CB1 antagonist  Morphine, heroin  CPP, SA  Attenuation  Chaperon 1999; 
        Braida 2001; Navarro 2001;
        MasNieto 2001; Caille and 
        Parsons 2003; De Vries 2003;
        Fattore 2003, 2005; Navarro
         2004; Cohen 2002; Solinas
      2003;  Maldonado  2006
  Heroin  SA (relapse)  Reinstatement attenuation   De Vries 2003; Fattore 2003
CB1 KO  Morphine  Withdrawal  Attenuation  Ledent 1999; Lichtman 2001
    CPP, SA  Suppression, attenuation,  Ledent 1999; Cossu 2001 
        no change  Martin 2000; Rice 2002
with abrupt termination of drug action (administration of a 
selective antagonist after chronic exposure).
The endocannabinoid system 
in opioid addiction
Opioids and cannabinoids have several similar pharma-
cological effects, including analgesia and stimulation of 
brain circuitry, that are believed to underlie drug addic-
tion and reward. There is ample evidence of a role for the 
endocannabinoid system in opioid dependence (Table 1). 
Cannabinoids attenuated morphine and methadone with-
drawal signs (Hine et al 1975; Deikel and Carder 1976; 
Vela et al 1995; Yamaguchi et al 2001; Del Arco et al 2002) 
and the cannabinoid antagonist SR141716A precipitated 
abstinence in morphine-dependent rats (Navarro et al 1998; 
Maldonado 2002). The severity of naloxone-precipitated 
morphine withdrawal was robustly attenuated in CB1 ko 
mice (Ledent et al 1999; Lichtman et al 2001) and long-
term treatment with SR141716A reduced the intensity of 
naloxone-precipitated opioid withdrawal (Rubino et al 
2000; Mas Nieto et al 2001); however an acute dose of 
SR141716A just before naloxone did not affect the inci-
dence of withdrawal signs (Mas-Nieto et al 2001).
Thus it appears that chronic blockade of CB1 receptors 
is needed to alleviate the main signs of morphine abstinence, 
suggesting that chronic treatment with SR141716A might 
be useful in the opiate withdrawal syndrome. In addition 
changes in CB1 receptor function (in terms of receptor 
binding and coupling with G protein) and/or in endocan-
nabinoid levels were observed in speciﬁ  c brain areas of 
morphine-dependent animals, although the results ranged 
from no change to a decrease or even an increase (Romero 
et al 1998; Gonzalez et al 2003; Viganò et al 2005).
The opioid antagonist naloxone precipitated abstinence 
symptoms in rats tolerant to Δ9-tetrahydrocannabinol 
(Δ9-THC) (Kaymakcalan et al 1977) and SR141716A-
precipitated withdrawal was dose-dependently reduced by 
morphine (Lichtman et al 2001). The somatic expression 
of cannabinoid withdrawal was attenuated in mice lacking 
pre-pro-enkephalin or mu opioid receptor genes (Valverde 
et al 2000; Lichtman et al 2001) whereas the deletion of 
mu, kappa and delta opioid receptors did not affect can-
nabinoid withdrawal (Ghozland et al 2002). In contrast, in 
double ko mice deﬁ  cient in mu and delta opioid receptors, 
cannabinoid withdrawal was signiﬁ  cantly reduced (Cas-
tane et al 2003), suggesting that a cooperative action of 
both receptors was required for the expression of Δ9-THC 
dependence.
The traditional animal paradigm of drug dependence 
further conﬁ  rmed the importance of the endocannabinoid 
system in opioid addiction. Manzanedo et al (2004) reported 
that pre-exposure to the synthetic cannabinoid agonist 
WIN55212-2 increased the rewarding effect of morphine 
evaluated in a place preference paradigm, supporting the idea Neuropsychiatric Disease and Treatment 2007:3(6) 714
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that using cannabis might make an individual more vulner-
able to opiate addiction. More recently, Goldberg’s group 
(Solinas et al 2005) reported that the reinforcing efﬁ  cacy 
of heroin, measured in a progressive ratio schedule of i.v. 
heroin self-administration, was signiﬁ  cantly enhanced by 
Δ9-THC and WIN55212-2 but not by compounds that raise 
the levels of endocannabinoids by blocking their uptake or 
metabolism; this suggested that the interaction between can-
nabinoids and opioids might be mediated by their receptors 
and signaling pathways rather than by opioid-induced release 
of endogenous cannabinoids.
In contrast, approaches involving the CB1 receptor 
antagonist SR141716A suggested the endocannabinoids had a 
facilitating effect on opioid reinforcement that was unmasked 
by CB1 receptor blockade. SR141716A reduced opioid self-
administration and conditioned place preference in rodents 
(Chaperon et al 1999; Braida et al 2001; Navarro et al 2001, 
2004; Mas Nieto et al 2001; Caille and Parsons 2003; De Vries 
et al 2003; Fattore et al 2003; see for review Fattore et al 2005 
and Maldonado et al 2006). SR141716A had more effect on 
heroin self-administration when more effort was required to 
obtain a heroin infusion; for example it was efﬁ  cacious under 
a progressive ratio schedule of reinforcement (high price of 
drug), weaker under a ﬁ  xed ratio schedule 5 (low price of 
drug) and null under a ﬁ  xed ratio schedule 1 (very low price) 
(Solinas et al 2003).
These results strengthen the idea that SR141716A attenu-
ates the reinforcing effects of heroin and provide support for 
the potential efﬁ  cacy of cannabinoid CB1 antagonists in the 
prevention and treatment of opioid reward. Thus, morphine 
conditioned place preference (Martin et al 2000) and self-
administration (Ledent et al 1999; Cossu et al 2001) were 
abolished in CB ko mice although the results on morphine 
CPP in CB1 ko mice tended to vary. Martin et al (2000) 
found morphine induced CPP in wild-type mice but there 
was no such response in ko mice, indicating that the drug 
had no rewarding effects in the absence of CB1 cannabinoid 
receptors. Rice et al in 2002, reported that CB1 receptor ko 
mice developed a strong place preference to morphine, simi-
lar to that in wild-type Swiss-Webster mice; this indicated 
that the brain cannabinoid system made no contribution to 
morphine reward.
One explanation of these conﬂ  icting results might be 
found in the slightly more intensive conditioning paradigm 
and differences in the conditioning chambers used in the 
last study.
In summary, the cannabinoid system plays a permissive 
role in opioid motivational and rewarding properties. The 
rewarding effects of Δ9-THC were suppressed in opioid-
receptor ko mice (Ghozland et al 2002; Castane et al 2003) 
and attenuated by opioid antagonists (Braida et al 2001; 
Justinova et al 2004).
It is interesting that SR141716A did not modify the 
dopamine releasing effect of heroin in the NAc (Tanda 
and Di Chiara 1997; Caille and Parsons 2003). Caille and 
Parsons (2006) have subsequently focused on an addi-
tional substrate in opiate reward, namely the ventromedial 
pallidum (VP), a cerebral area that receives dense GAB-
Aergic input from the NAc. Opiates strongly reduced VP 
GABA efﬂ  ux and the resulting disinhibition of the VP is 
thought to contribute to the positive reinforcing effects of 
opiates (Caille and Parsons 2004). SR141716A caused a 
dose-dependent blockade of the effect of morphine on VP 
GABA efﬂ  ux without inﬂ  uencing morphine’s dopamine-
releasing effect. However, SR14716A did not alter cocaine 
self-administration, or cocaine-induced decrements in 
VP GABA efﬂ  ux and increases in NAc dopamine. This 
is consistent with evidence that selective inactivation of 
CB1 receptors reduces opiate-, but not psychostimulant-
maintained self-administration. However, the CB1 recep-
tor agonist WIN55212-2 reduced VP GABA efﬂ  ux in a 
manner similar to morphine, and this effect was reversed 
by the opiate receptor antagonist naloxone. These results 
point to an interaction between cannabinoids and opioids in 
their effects on VP activity, and suggest that SR141716A 
attenuates opiate reward by reducing the opiates’ inhibitory 
inﬂ  uence on NAc medium spiny neurons.
Finally, endocannabinoid tone seems to have a particu-
larly interesting role in relapse to opiate abuse, especially 
in humans. Detoxiﬁ  cation from opiate addiction has been 
a medical problem for as long as opiates have been abused, 
as relapses occur even after long drug-free periods. The 
endocannabinoid system almost certainly plays a part in 
triggering or preventing reinstatement of drug-seeking 
behavior (see for review Fattore et al 2006).
The three synthetic CB1 receptor agonists WIN55212-2, 
CP55940 and HU210 promptly reinstate heroin-seeking after 
a long drug-free period (De Vries et al 2003; Fattore et al 
2003). Rimonabant, however, attenuates heroin-induced rein-
statement of heroin-seeking behavior (De Vries et al 2003; 
Fattore et al 2003) suggesting that CB1 receptor blockade 
alters heroin’s reinforcing consequences.
Further supporting the notion of a close reciprocal rela-
tionship between cannabinoid and opioid systems in relapse, 
blockade of opioid receptors by naloxone prevented relapse 
to cannabinoids (Spano et al 2004) and a priming injection Neuropsychiatric Disease and Treatment 2007:3(6) 715
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Table 2 Cannabinoid system in nicotine and alcohol addiction
Nicotine Model  Effect  Refs
CB1 agonist  Withdrawal  Attenuation, increase  Balerio 2004;
     Valjent  2002
CB1 antagonist  CPP  Increase   Valjent 2002
  CPP  Attenuation  Le Foll and Goldberg
     2004
  CPP  Suppression short-term  Forget 2005
   expression 
  SA  Attenuation   Cohen 2002
  SA (relapse)  Attenuation nicotine-  Cohen 2005 
     associated  cues
  STRATUS-US trial  Increase quit rate in humans  Anthenelli and Despres
     2004
CB1 KO  CPP  Suppression  Castane 2002
  SA  No change  Cossu 2001
Alcohol    
CB1 agonist  Voluntary consumption  Increase intake in alcohol-  Colombo 2002;
      preferring rats and mice  Wang 2003
    Increase break point in rats  Gallate 1999
   (beer)
  Voluntary consumption  Prevents acquisition of   Serra 2001;
      drinking behaviour in   Gessa 2005
     alcohol-preferring  rats
    Attenuation of ethanol   Arnone 1997;
      consumption in mice, in  Colombo 1998;
      alcohol-preferring rats   Lallemand 2001;
     and  Wistar  rats  Gessa  2005;
     Cippitelli  2005;
CB1 antagonist  SA  Reduction in unselected rats  Gallate and Mc Gregor 1999;
     Freedland  2001;
     Colombo  2004
  SA (relapse)  Suppression of alcohol   Serra 2002
     deprivation  effect
CB1 KO  Withdrawal  Increase  Naassila 2004
  Voluntary consumption  Attenuation  Naassila 2004
 
FAAH KO,   SA, Voluntary consumption  Increase motivation  Basavarajappa 2006;
FAAH inhibitor      to drink  Hansson 2006
of heroin reinstated cannabinoid-seeking behavior after 
three weeks of extinction. Interestingly, SR141716A per se 
did not reinstate responding but did prevent cannabinoid-
seeking behavior triggered by heroin (Spano et al 2004).
The endocannabinoid system 
in nicotine addiction
There appears to be a functional interaction between the 
endogenous cannabinoid system and nicotine addiction 
(Table 2). In the mouse CPP paradigm, co-administration 
of sub-threshold doses of Δ9-THC and nicotine induced 
rewarding effects (Valjent et al 2002). Acute Δ9-THC signiﬁ  -
cantly lowered the incidence of several precipitated nicotine 
withdrawal signs and improved the aversive motivational 
consequences of nicotine withdrawal in mice (Balerio et al 
2004). These ﬁ  ndings suggest that each drug enhances the 
rewarding effect of the other, and that cannabis might be 
used to reduce aversive reactions resulting from nicotine 
withdrawal. In contrast, Valjent et al (2002) showed an 
enhancement in the somatic expression of withdrawal in 
animals co-treated with nicotine and Δ9-THC, suggesting 
an asymmetric relationship between the two compounds. 
Nicotine had no rewarding effect in CB1 ko mice in a place 
preference paradigm (Castane et al 2002). By contrast, Cossu 
et al (2001) reported that the absence of CB1 receptors did not 
affect nicotine self-administration. Methodological aspects 
such as the speciﬁ  c paradigm and the dose used may partly 
explain this discrepancy.Neuropsychiatric Disease and Treatment 2007:3(6) 716
Parolaro et al
The second approach used to demonstrate the endo-
cannabinoid system’s role in nicotine addiction involves 
SR141716A. Pretreatment with this speciﬁ  c CB1 recep-
tor antagonist reduced nicotine self-administration, 
nicotine-seeking behavior induced by conditioned cues in 
rats (Le Foll and Goldberg 2004; Cohen et al 2005), nicotine-
induced dopamine release in the NAc (Cohen et al 2002) 
and the dopaminergic component of nicotine discrimination 
(Cohen et al 2002).
To conclude, since dopamine release in the NAc is thought 
to play a major role in the positive reinforcement of nicotine, 
and although ﬁ  ndings in CB1 receptor ko mice are inconsistent, 
SR141716A may well have some antismoking activity, by 
reducing the rewarding/reinforcing effect of nicotine.
Some recent papers have looked at the utility of 
SR141716A for reducing cues associated with nicotine-
seeking behavior, one of the major causes of relapse in for-
mer smokers. Forget et al (2005) showed that SR141716A 
impaired both the establishment and the short-term expres-
sion of CPP induced by nicotine, suggesting that endogenous 
cannabinoids are implicated in nicotine’s motivational 
effects. Interestingly, rimonabant did not affect the long-
term expression of the incentive learning, suggesting 
other cannabinoid-independent mechanisms are involved 
(Forget et al 2005). However, Cohen et al (2005) found that 
rimonabant attenuated the long-term inﬂ  uence of environ-
mental stimuli responsible for relapse in nicotine-seeking 
behavior. After demonstrating the persistence of condi-
tioned behavior in response to nicotine-related cues several 
weeks after nicotine withdrawal, Cohen et al showed that 
rimonabant could reduce the responding maintained by these 
cues three months after stopping smoking. Thus rimonabant 
may not only help stop people smoking but may also help 
them remain abstinent.
Biochemical investigations found altered levels of AEA 
and 2-AG in several brain areas in animals chronically treated 
with nicotine. AEA was elevated in the limbic area and brain-
stem, and 2-AG in the brainstem, but one or both were reduced 
in other regions such as hippocampus, striatum and cerebral 
cortex. CB1 receptor levels were not altered in any of these 
brain areas (Gonzalez et al 2002; Balerio et al 2004).
To summarize, the pharmacological and cellular studies 
described indicate that the endogenous cannabinoid system 
has a speciﬁ  c role in nicotine responses related to its addictive 
behavior and open up new possibilities for the treatment of 
this major public health disorder.
There are already some preliminary data from the 
STRATUS-US trial (smoking cessation in smokers motivated 
to quit) on the efﬁ  cacy of rimonabant in humans (Anthenelli 
and Despres 2004). This clinical trial enrolled 787 smokers 
in the United States. The participants were randomized to 
rimonabant 5 mg or 20 mg, or placebo. The study lasted ten 
weeks and the smokers were allowed to smoke during the 
ﬁ  rst two weeks but were asked to abstain after this. The quit-
ting rate in the 2-mg rimonabant group was double that with 
placebo and they showed markedly less weight gain during 
the ten-week study period (Anthenelli and Despres 2004).
The endocannabinoid system 
in alcohol addiction
Recent studies suggest that the endocannabinoid system has 
a major part among the neurotransmitter systems involved 
in regulating different alcohol-related phenomena, including 
tolerance, vulnerability, reinforcement, consumption and 
metabolism (Table 2).Thus acute administration of synthetic 
or endogenous cannabinoid agonists stimulated alcohol intake 
in Sardinian alcohol-preferring rats (Colombo et al 2002) and 
C57BL/6J mice (Wang et al 2003), and dose-dependently 
increased break points (an indicator of motivation to drink 
alcohol) for beer in Wistar rats (Gallate et al 1999). All 
these effects were completely prevented by pre-treatment 
with the cannabinoid antagonist SR141716A. Furthermore, 
genetic deletion of the FAAH enzyme (Basavarajappa et al 
2006) or an injection of URB597 (an irreversible FAAH 
inhibitor) into the prefrontal cortex enhanced motivation 
to drink alcohol (Hansson et al 2006), pointing clearly to a 
role for the endocannabinoid system in alcohol addiction. It 
is in fact now established that SR141716A, given alone, has 
effects on alcohol-related behavior opposite to those of the 
CB1 receptor agonists. For example, SR141716A prevented 
the acquisition of alcohol drinking behavior in alcohol-naïve 
Sardinian alcohol-preferring rats with a free choice between 
alcohol (10%, v/v) and water (Serra et al 2001). It also 
reduced ethanol consumption in C57Bl/6 mice at doses only 
marginally affecting regular chow intake or water drinking; 
this suggests that the endogenous cannabinoid system may 
affect the appetitive value of ethanol (Arnone et al 1997).
Similar reductions in voluntary alcohol intake were 
obtained in Sardinian alcohol-preferring rats (Colombo et al 
1998), and Wistar rats (Lallemand et al 2001) after chronic 
alcoholization (a model of the “maintenance” phase of human 
alcoholism). In the Sardinian alcohol-preferring rats the CB1 
receptor antagonist completely abolished the effect of alco-
hol deprivation (ie, the temporary increase in alcohol intake 
after a period of withdrawal, a model for relapse episodes in 
human alcoholics). This suggested that the cannabinoid CB1 Neuropsychiatric Disease and Treatment 2007:3(6) 717
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receptor might be part of the neural substrate of the alcohol 
deprivation effect and that SR141716A may have anti-relapse 
properties (Serra et al 2002).
Finally, SR141716A reduced oral self-administration and 
attenuated the appetitive properties of alcohol in unselected 
rats under operant procedures (Gallate and McGregor 1999; 
Freedland et al 2001; Colombo et al 2004). These data were 
conﬁ  rmed by Gessa et al (2005) using a second CB1 receptor 
antagonist, the newly synthesized SR147778, which sup-
pressed acquisition and maintenance of alcohol drinking, 
relapse-like drinking and motivation to consume alcohol 
in Sardinian alcohol-preferring rats. Cippitelli et al (2005) 
provided clear evidence that blockade of CB1 receptors 
reduced both ethanol self-administration and conditioned 
reinstatement of alcohol-seeking behavior in Marchigian-
Sardinian alcohol-preferring rats and Wistar rats, the geneti-
cally selected rats showing higher sensitivity to rimonabant. 
These researchers also reported that at least in the strain of 
rats bred for its ethanol preference, the Marchigian-Sardinian 
alcohol-preferring rats, CB1 cannabinoid receptor mRNA 
expression was increased in brain areas relevant for pro-
cessing reward and reward-associated behavior, suggesting 
that alterations in the function of the CB1 receptor system 
may be linked to genetic vulnerability to alcohol misuse 
(Cippitelli et al 2005).
All these results further reinforce the concept that 
pharmacological blockade of the CB1 receptor may offer a 
novel approach to the treatment of alcoholism, not only for 
consumption but also for context-induced relapses to alcohol, 
one of the main problems in the treatment of this disorder.
The CB1 receptor signaling system’s participation in 
alcohol drinking and alcohol sensitivity was conﬁ  rmed using 
CB1 receptor ko mice. CB1 -/- mice with CD1 background 
showed lower ethanol intake and less preference, effects 
associated with dramatic sensitivity to the hypothermic and 
hypolocomotor effects in response to low doses of ethanol 
(Naassila et al 2004). These mice also had more severe 
withdrawal-induced convulsions. Since previous studies in 
rodents have suggested that high levels of ethanol drink-
ing are often associated with resistance to its intoxicant 
effects (Schuckit 1994; Kurtz et al 1996), the lower ethanol 
consumption in CB1 ko mice might be due to their greater 
sensitivity to ethanol’s acute effects.
Chronic in vivo (Gonzalez et al 2002) or in vitro 
(Basavarajappa and Hungund, 1999a; Basavarajappa et al 
2003) ethanol exposure increased accumulation of AEA. 
This was inhibited by pertussis toxin and the CB1 receptor 
antagonist SR141716A, and paralleled by the activation of 
Ca2+-dependent and arachidonic acid-speciﬁ  c phospholipase 
A2, a key enzyme in the formation of endocannabinoids in 
neuronal cells and brain (Basavarajappa et al 1997, 1998). 
The mechanism by which chronic ethanol exposure increases 
the endocannabinoid content remains to be established, 
though Basavarajappa et al (2003) have reported that in 
cerebellar granular neurons chronic exposure to alcohol led 
to an increase in extracellular AEA by inhibiting its uptake. 
This event was CB1 receptor-independent since it also 
occurred in CB1 ko mice and cannabinoid CB1 receptor 
antagonists did not alter the effects of chronic ethanol on 
AEA transport. Moreover, in rodents chronic exposure to 
alcohol impairs CB1 receptor function, lowering the levels 
of CB1 receptor binding, expression and CB1 receptor/G 
protein coupling (Basavarajappa and Hungund 1999b; Ortiz 
et al 2004). This might be due to overstimulation of receptors 
through increased endocannabinoid synthesis. These studies 
suggest that during the development of alcohol tolerance 
there are changes in the steady state in the endogenous can-
nabinoid system, and this might explain the altered response 
to alcohol.
These converging ﬁ  ndings suggest that cannabinoid CB1 
receptor blockade may be an effective therapeutic approach 
for alcohol dependence in humans but information on the 
clinical efﬁ  cacy of rimonabant is still lacking.
The endocannabinoid system 
in addiction to psychostimulants
Psychostimulants differ from the drugs of abuse since they 
affect mesolimbic dopaminergic terminals directly, raising 
dopamine levels in the NAc by direct action on dopaminergic 
axon terminals; the other drugs seem to induce rewarding 
effects by increasing dopaminergic neuron ﬁ  ring rates, acting 
in the VTA, possibly through the release of endocannabinoids 
(Lupica and Riegel 2005).
This may help us understand why endocannabinoids 
are not involved in cocaine’s or amphetamine’s primary 
reinforcing effects. In fact, there are several reports 
(Table 3) that genetic deletion or pharmacological blockade 
of CB1 receptors does not alter cocaine or amphetamine 
self-administration (Cossu et al 2001; De Vries et al 2001; 
Braida et al 2005; Lesscher et al 2005) or the neurochemical 
correlate of this behavior, namely dopamine release in the 
NAc (Cossu, unpublished results, Soria et al 2005). Similarly, 
cocaine-induced CPP was not modiﬁ  ed in CB1 ko mice 
(Martin et al 2000; Houchi et al 2005). These results clearly 
indicate that CB1 receptors are probably not involved in the 
primary reinforcing effects of psychostimulants.Neuropsychiatric Disease and Treatment 2007:3(6) 718
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Table 3 Cannabinoid system in psychostimulant addiction
 Drug  Model  Effect  Refs
CB1 agonist  Cocaine  CPP   Decrease  Fattore 1999
  Amphetamine  SA  Decrease  Braida and Sala 2002
 Cocaine  SA  (relapse)  Increase  De  Vries  2001
CB1 antagonist  Amphetamine  CPP  Attenuation   Braida 2005
  Cocaine  SA  No change  Lesscher 2005
    SA  Attenuation   Soria 2005
    SA (relapse)  Attenuation   De Vries 2001
  Amphetamine,  SA (relapse)  Inhibits reinstatement of  Xi 2006;
  Cocaine      reward-seeking behavior  Anggadiredja 2004
CB1 KO  Cocaine  CPP  No change  Martin 2000; 
       Houchi  2005
    SA  Attenuation   Soria 2005
  Amphetamine,  SA  No change  Cossu 2001
 Cocaine
Although acute reinforcing properties are essential for the 
establishment of drug addiction, other complex behavioral 
processes are involved in consolidating this chronic relapsing 
disorder (Koob and LeMoal 2001), so the acute reinforcing 
effects of the drug are only the ﬁ  rst step in the acquisition 
of stable operant self-administration responding. Besides the 
mesolimbic dopaminergic system, particularly the NAc, it has 
been proposed that dopamine-independent neuronal circuits 
are involved in regulating reward-related processes (Lupica 
et al 2004). CB1 cannabinoid receptors are highly expressed 
in other brain regions involved in the rewarding circuitry such 
as the basolateral amygdala, medial prefrontal cortex, and 
hippocampus, so mechanisms involving CB1 receptors in 
these structures might well participate in other aspects such 
as consolidation and relapse of cocaine-seeking behavior. 
In line with this hypothesis, Soria et al (2005) found that 
only 25% of CB1 ko mice, compared with 75% of the wild-
type, acquired reliable operant responding to self-administer 
the most effective dose of cocaine (1 mg/kg/infusion), and 
needed more sessions to attain this behavior. Moreover, the 
maximal effort to obtain a cocaine infusion was signiﬁ  cantly 
lower after genetic ablation of CB1 receptors, indicating 
decreased motivation for maintaining cocaine-seeking behav-
ior. Results were similar after pharmacological blockade of 
CB1 receptors with SR141716A in wild-type litter mates 
(Soria et al 2005). The lack of motivation for cocaine in 
CB1 ko or SR141716A-pretreated mice might be due to 
impaired detection, association, and representation of the 
reward signal or to inadequate responding to the rewarding 
stimuli (Soria et al 2005).
In line with the idea of CB1 receptors involved in these 
other aspects of reward, Fattore et al (1999) found that WIN 
55212-2 reduced intravenous cocaine self-administration, 
suggesting that stimulation of CB1 receptors may potentiate 
cocaine’s reinforcing effects. Similar ﬁ  ndings were reported 
with amphetamine (Braida and Sala 2002): the combination 
of CP-55,940 with the maximal reinforcing unit dose of 
3,4-methylendioxymethamphetamine (MDMA) signiﬁ  cantly 
lowered the mean number of drug-associated lever pressings 
in comparison with the drug alone, suggesting a synergistic 
action of cannabinoid agonists on MDMA’s reinforcing 
properties.
Finally, CB1 receptors play an important role in 
relapse to psychostimulants. De Vries et al (2001) found 
that the cannabinoid agonist HU210 provoked relapse to 
drug-seeking in animals after prolonged withdrawal from 
cocaine self-administration, whereas blockade of the CB1 
receptor by SR141716A attenuated the relapse induced by 
re-exposure to cocaine-associated cues or the drug itself. 
Xi et al (2006) have now shown that the CB1 antagonist 
AM251, administered systemically, selectively inhibited 
cocaine-induced reinstatement of reward-seeking behavior 
by a glutamate-dependent mechanism. CB1 receptor-medi-
ated disinhibition of NAc glutamate release could activate 
presynaptic mGluR2/3 receptors, which then inhibited 
cocaine-enhanced NAc glutamate release and cocaine-
triggered reinstatement of drug-seeking behavior (Xi et al 
2006). Along the same lines, SR141716A blocked the 
reinstatement of methamphetamine-seeking behavior in 
rats (Anggadidiredja et al 2004).
Given the paucity of effective medications to treat psy-
chostimulant addiction, and although the endocannabinoid 
system does not participate in the primary reinforcing effects 
of this class of drugs, CB1 receptor antagonists may offer 
hope for treating consolidated psychostimulant-seeking 
behavior and relapse.Neuropsychiatric Disease and Treatment 2007:3(6) 719
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Conclusions and future directions
In the last 25 years the neurobiological and behavioral mecha-
nisms that lead to drug dependence have been extensively 
investigated but clinical treatment is still unsatisfactory and 
ineffective in many subjects.
Experimental models are now providing evidence for the 
pharmacological management of endocannabinoid signaling 
not only to block the direct reinforcing effects of cannabis, 
opioids, nicotine and ethanol, but also to prevent relapse to 
these various substances of abuse, also including cocaine 
and metamphetamine. The endocannabinoid system can be 
manipulated by SR141716A and by all the new compounds 
that protect AEA and 2-AG from deactivation and prolong 
the lifespan of these endocannabinoid substances in vivo. 
Rimonabant reduces the motivational effect of drug-related 
stimuli and drug re-exposure, probably by altering synaptic 
plasticity, thus providing an effective means of preventing 
relapse and a new tool for the treatment of drug abuse.
Although further studies are needed to clarify the precise 
mechanism underlying the endocannabinoid system’s role in 
addiction, some promising clinical ﬁ  ndings have now been 
presented (eg, smoking cessation). A new question has now 
arisen from the discovery of CB2 receptors in the brain: are 
they involved in drug addiction?
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